Orexigen Therapeutics (OREX) Tops Q3 EPS by 7c, Revenue Misses

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Orexigen Therapeutics (OREX) Tops Q3 EPS by 7c, Revenue Misses

Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015

November 5, 2015 4:01 PM EST

SAN DIEGO, Nov. 5, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2015.

"In the first 12 months since the U.S. launch, we have been encouraged by gross demand for Contrave, with well over 500,000 prescriptions written by approximately 50,000 physicians," said Mike Narachi, CEO of Orexigen. "In the coming year, we expect the overall market for anti-obesity medicines to grow significantly year over year and for Contrave to continue to gain overall market share."

Recent Business Highlights:

According to IMS... More